Open an account

Ultralife

ULBI · NASDAQ

$6.29+$0.23 (+3.80%)TodayMarket closed ·
Prev close $6.06

ULBI analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Nov 24, 2024

Bull case

Ultralife Corp experienced a strong top-line sales growth of 23.4% year-over-year, driven by record medical sales and significant increases in both Government and Defense (G&D) and Commercial segments, at 28.8% and 20.2% respectively. The company reported an improved gross profit margin of 25.6%, up from 22.4% year-over-year, reflecting enhanced operational efficiency amid the easing of supply chain constraints. Additionally, the positive cash flow from operations has enabled the company to initiate debt repayment, reducing interest burdens and positioning it favorably for continued growth as it launches new products and integrates the recent acquisition of ElectroChem.

Bear case

Ultralife Corp reported third-quarter revenues of $35.7 million, a decrease from $39.5 million year-over-year and falling short of the $43 million estimate. The company's adjusted EBITDA of $1.9 million also significantly underperformed expectations, being lower than the forecasted $5.2 million due to weaker top-line results. Contributing to this negative outlook, Ultralife faced supply chain challenges and delays in fulfilling large customer orders across both its Communications Systems and Battery & Energy Products segments.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.